

TCR signals fuel T_{reg} cells

Christoph Drees, J. Christoph Vahl and Marc Schmidt-Supprian

Regulatory T (T_{reg}) cells safeguard against autoimmunity and overshooting inflammation. During their development in the thymus, T_{reg} cells are selected by stronger autoantigenic T cell receptor (TCR) signals than conventional T cells. These TCR signals are critically important for the initiation of two key lineage defining events, namely induction of the transcription factor Foxp3 and hypomethylation of a specific gene set. Recent studies shed light on the role of continuous (autoreactive) TCR signals for identity, homeostasis and functions of mature T_{reg} cells.

Induced TCR ablation on mature T_{reg} cells only minimally reduces Foxp3 expression [1, 2] and does not affect hypomethylation patterns [1]. Stable Foxp3 expression was also observed in T_{reg} cells lacking the TCR signal transduction proteins Lck [3] or SLP-76 [4] and upon ablation of the co-stimulatory receptor CD28 [5]. Fittingly, mature T_{reg} cells, expressing a TCR but deprived of peripheral autoantigenic stimulation due to lack of MHC II on hematopoietic cells, still express Foxp3 [6]. Therefore, once a core T_{reg} cell identity has been established in the thymus, it is maintained independently of peripheral TCR signals.

In contrast, the T_{reg} cell surface phenotype and their signature gene expression were strongly affected by the various means of inhibiting TCR signals [1-3, 6]. However, the peripheral T_{reg} cell pool is heterogeneous in that it consists of naïve and various subsets of effector-like T_{reg} cells. Induced TCR ablation showed that, at least under homeostatic conditions in healthy mice, effector-like T_{reg} cells strictly depend on TCR signals for their generation and/or maintenance. Attempts to distinguish between naïve and effector-like T_{reg} cells based on CD62L/CD44 [2] or CD25 [1] expression revealed that both require TCR signals to maintain their characteristic surface phenotype and gene expression, independently of their homeostasis. Interestingly, apart from reduced levels of TCR-activated transcription factors such as Egr2 and c-Rel and their respective target genes, loss of TCR signals strongly affects IRF4-controlled genes. The concept that DNA hypomethylation ensures the expression of key T_{reg} cell genes is supported by the reduced, but still robust expression of CTLA-4, GITR and Eos of TCR-deficient T_{reg} cells [1].

Both induced TCR and co-stimulatory CD28 ablation cause a decline in T_{reg} cells in the absence of thymic T cell production, which goes hand in hand with completely abrogated [1] or reduced [5] homeostatic

proliferation, respectively. This is not due to reduced responsiveness to homeostatic cytokines, such as IL-2. Interestingly, T_{reg} cells deprived of MHC II contact proliferate well in response to anti-CD3 stimulation [6] and TCR-deficient T_{reg} cells divide when stimulated with TCR-bypassing PMA/Ionomycin [2], indicating that these cells do not become anergic to proliferation-inducing signals. The protein levels of Bcl-2 and Bim are two-fold upregulated in T_{reg} cells upon TCR loss, to the same levels as in naïve CD4 T cells [1]. However, none of the studies reported a significant difference in survival between TCR signaling impaired and normal T_{reg} cells *in vivo*, and BrdU pulse-chase experiments suggest impaired turnover/proliferation, but normal survival of Lck-deficient T_{reg} cells [3]. Collectively, these experiments show that TCR signal-induced proliferation forms an essential homeostatic requirement for all T_{reg} cell subsets.

T_{reg} cells suppress immune responses through the release of inhibitory cytokines, competition for IL-2, access to and functional modulation of antigen presenting cells and direct cytotoxic killing. TCR-deficient T_{reg} cells show reduced expression of inhibitory and cytotoxic molecules including IL-10 and Granzyme B. In addition, the expression of proteins through which T_{reg} cells regulate the functions of antigen presenting cells, such as CTLA-4, NT5E/CD73, LFA-1 and NRP1, is significantly reduced [1, 2, 6]. TCR signaling impaired T_{reg} cells fail to efficiently suppress T cell activation and proliferation *in vitro* [3-6]. Conversely, augmenting TCR signaling by ablating the DAG-metabolizing kinase DGK ζ enhances the *in vitro* suppression capacity [4]. Importantly, T_{reg} cells require constant TCR signals to sustain their suppressive abilities *in vivo*: MHC II contact-deprived T_{reg} cells fail to control naïve T cell expansion upon co-transfer [6], TCR-deficient T_{reg} cells cannot control effector T cell differentiation/proliferation and cytokine production *in situ* [2] and induced TCR ablation limits T_{reg} cell-mediated control of colitis and EAE [1]. Therefore, TCR signals continuously arm T_{reg} cells for suppression, in addition to their role in their homeostasis.

Expression height of Ly-6C, which is strongly elevated in Lck-deficient [3] and TCR-deficient [1] T_{reg} cells, appears to differentiate T_{reg} cells receiving strong TCR signals (Ly-6C-) from those that do not (Ly-6C+) [7]. Purified Ly-6C- and Ly-6C+ T_{reg} cells differed dramatically in phenotype, gene expression and their ability to suppress *in vitro* and *in vivo*. Accordingly, effector T_{reg} cells are exclusively Ly-6C-. However, on average half

of the TCR-deficient T_{reg} cells lacked Ly-6C (Vahl et al., unpublished), showing that not all Ly-6C- T_{reg} cells result from continuous TCR triggering. Modern multiparameter flow cytometry should help to further unravel the dynamic complexities of T_{reg} cell subsets.

In summary, we conclude that while TCR signals are dispensable for maintaining the core T_{reg} cell identity, they are continuously fueling their homeostasis, effector differentiation and suppressive functions.

Marc Schmidt-Supprian: Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Correspondence to: Marc Schmidt-Supprian, **email** supprian@gmail.com

Keywords: Immunology and Microbiology Section, Immune response, Immunity

Received: July 01, 2015

Published: July 12, 2015

REFERENCES

1. Vahl JC et al. *Immunity* 2014; 41:722-36.
2. Levine AG et al. *Nat Immunol* 2014; 15:1070-8.
3. Kim JK et al. *PLoS ONE* 2009; 4:e6580.
4. Schmidt AM et al. *The Journal of Immunology* 2015; 194:4362-70.
5. Gogishvili T et al. *Eur J Immunol* 2012; 43:188-93.
6. Delpoux A et al. *Eur J Immunol* 2012; 42:1237-49.
7. Delpoux A et al. *The Journal of Immunology* 2014; 193:5914-23.